title: Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II study.
abstract: BACKGROUND
  A systemic and intraventricular polychemotherapy regimen (the Bonn protocol) without radiotherapy resulted in durable responses in 75% of patients <60 years with primary CNS lymphoma (PCNSL), but was complicated by a high rate of Ommaya reservoir infections. Here, the efficacy and toxicity of this regimen without intraventricular treatment was evaluated in PCNSL.
  
  
  METHODS
  From August 2003 to November 2005, 18 patients with PCNSL <60 years (median age, 53 years) were treated in a phase II trial with a high-dose methotrexate (MTX; cycles 1, 2, 4 and 5) and cytarabine (Ara-C; cycles 3 and 6) based systemic therapy including dexamethasone, vinca-alkaloids, ifosfamide and cyclophosphamide.
  
  
  RESULTS
  Study accrual was prematurely stopped in November 2005 due to a high rate of early relapses. Seventeen of 18 patients were assessable for response: nine (53%) achieved complete response (CR), two (12%) complete response/unconfirmed (CRu) and two (12%) partial response (PR); four (24%) showed progressive disease (PD). One treatment was stopped due to toxicity. Median follow-up was 23 months, median response duration was only 10 months in responding patients, and median time to treatment failure (TTF) was 8 months in the whole group. Median overall survival (OS) has not been reached. Systemic toxicity was mainly hematologic.
  
  
  CONCLUSIONS
  In PCNSL patients <60 years, polychemotherapy without intraventricular treatment results in a high response rate, but is associated with early relapses in the majority of cases. This is in contrast to the results achieved with the same protocol but with intraventricular treatment.
authors.affiliation: Department of Neurology, Knappschaftskrankenhaus, University of Bochum, In der Schornau 23-25, Bochum, Germany.
authors.forename: Hendrik
authors.initials: H
authors.lastname: Pels
authors.forename: Annika
authors.initials: A
authors.lastname: Juergens
authors.forename: Axel
authors.initials: A
authors.lastname: Glasmacher
authors.forename: Holger
authors.initials: H
authors.lastname: Schulz
authors.forename: Andreas
authors.initials: A
authors.lastname: Engert
authors.forename: Michael
authors.initials: M
authors.lastname: Linnebank
authors.forename: Gabriele
authors.initials: G
authors.lastname: Schackert
authors.forename: Heinz
authors.initials: H
authors.lastname: Reichmann
authors.forename: Frank
authors.initials: F
authors.lastname: Kroschinsky
authors.forename: Marlies
authors.initials: M
authors.lastname: Vogt-Schaden
authors.forename: Gerlinde
authors.initials: G
authors.lastname: Egerer
authors.forename: Udo
authors.initials: U
authors.lastname: Bode
authors.forename: Carlo
authors.initials: C
authors.lastname: Schaller
authors.forename: Monika
authors.initials: M
authors.lastname: Lamprecht
authors.forename: Peter
authors.initials: P
authors.lastname: Hau
authors.forename: Martina
authors.initials: M
authors.lastname: Deckert
authors.forename: Rolf
authors.initials: R
authors.lastname: Fimmers
authors.forename: Christopher
authors.initials: C
authors.lastname: Bangard
authors.forename: Ingo G H
authors.initials: IG
authors.lastname: Schmidt-Wolf
authors.forename: Uwe
authors.initials: U
authors.lastname: Schlegel
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016543:Central Nervous System Neoplasms / Q000188:drug therapy*; D004333:Drug Administration Routes; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D053208:Kaplan-Meier Estimate; D017567:Karnofsky Performance Status; D008223:Lymphoma / Q000188:drug therapy*; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies
chemical_list: D000970:Antineoplastic Agents